[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

@d_stock07734 Avatar @d_stock07734 d_stock

d_stock posts on X about $nwbo, drivers, investment, take the the most. They currently have XXX followers and XXX posts still getting attention that total XXXXX engagements in the last XX hours.

Engagements: XXXXX #

Engagements Line Chart

Mentions: XX #

Mentions Line Chart

Followers: XXX #

Followers Line Chart

CreatorRank: XXXXXXX #

CreatorRank Line Chart

Social Influence #

Social category influence stocks finance

Social topic influence $nwbo #2, drivers #1338, investment, take the, $40b, long term, dual, over the, dstock #1, $qure

Top assets mentioned uniQure N.V. (QURE)

Top Social Posts #

Top posts by engagements in the last XX hours

"@mazzulo_lorie @andrewcaravello Why would he leave for Regeneron as an associate director on field medical affairs Why did Roger Perlmutter take the CEO job of a startup one week after stepping down from Merck Did Merck place most of its $40b strategic investment after Perlmutter left"
X Link @d_stock07734 2025-10-15T22:01Z XXX followers, XXX engagements

"$NWBO It's interesting that Roche sponsored a trial on using the combination of XCR1 with DC vaccine and Atezolizumab (PD-L1 inhibitor) to treat late stage small cell lung cancer. Among XX patients enrolled XX% are PD-L1 negative. The results were presented one year ago. There will be a presentation on this trial next week. Long term survivors from Phase Ib-II trial of tumor-loaded monocyte-derived dendritic cell vaccination plus atezolizumab in ES-SCLC Not sure if the research institution at Spain is involved in the symphony. But it's good to see Roche has interest in DC vaccine therapy."
X Link @d_stock07734 2025-10-16T20:46Z XXX followers, 1566 engagements

"$NWBO It seems like Merck is going to file the approval of oral PCSK9 inhibitor (MK-0616) as the treatment for hypercholesterolemia. No doubt Merck knows that MK-0616 can be used for cancer treatment and it is among XX new growth drivers that have blockbuster potential. DoD (W81XWH-21-1-0532) once sponsored a trial on using Amgen's PCSK9 inhibitor (Evolocumab) in combination with BMS's two checking point inhibitors to treat lung cancer. Dr. Scott Antonia was the PI of the trial. Regeneron also sponsored a trial similar to the above one and the combination adopted in the trial is Regneron's"
X Link @d_stock07734 2025-10-09T04:43Z XXX followers, XXX engagements

"$NWBO BeOne Medicines Sonrotoclax (BCL2 inhibitor) Granted Breakthrough Therapy Designation by U.S. FDA BCL-2 inhibitorsenhance the anti-cancer immune response by improving dendritic cell (DC) function not just by killing cancer cells.By inhibiting BCL-2 these drugs boost DCs' ability to present antigens to T cells which activates them to fight tumors.This dual action can be particularly effective when combined with other immunotherapies likePD-1 inhibitorsas it synergizes to improve anti-tumor immunity. Getting more bang for their buck: BCL2 inhibitors boost dendritic-cell function to"
X Link @d_stock07734 2025-10-14T05:17Z XXX followers, 1023 engagements

"@mazzulo_lorie @andrewcaravello BPs would not take hectic working hours to complete the manufacturing facilities if they were not something concerning their future. Merck never chose the same type of hectic working hours to solve BCG shortage issue"
X Link @d_stock07734 2025-10-16T05:09Z XXX followers, XXX engagements

"@Michael48826289 If I am not mistaken TIGIT inhibitor is among XX new growth drivers that Merck repeatedly claim to have blockbuster potentials"
X Link @d_stock07734 2025-10-16T20:53Z XXX followers, XX engagements

"$NWBO Regeneron conducted a trial on using Garetosmab to get rid of Activin A protein related to an ultra-rare disease called Fibrodysplasia Ossificans Progressiva (FOP). Mutated genes related to the Activin A protein include ACVR1 ACVR2A and ACVR2B. Of course trials can be set up so that peptides derived from these three genes can be loaded on DCs to treat FOP. There could be one answer to many diseases Garetosmab is a monoclonal antibody that neutralizes the Activin A protein which Regeneron scientists discovered to be a critical protein in the development of HO lesions in people with FOP."
X Link @d_stock07734 2025-09-25T19:20Z XXX followers, 4032 engagements

"LP is a great master in playing chess. Take this ovarian cancer trial as an example on which $NWBO never released the results. What kind of combination adopted in the trial It is: DCVAX-L + cyclophosphamide + Bevacizumab + Prevnar So we have Roche's Bevacizumab and Pfizer's Prevnar. It is hard to believe that the trial was completed in 2009 and Merck got its first approval on keytruda in 2014. Study Start: 2007-11 Primary Completion(Actual): 2009-12 Study Completion(Actual): 2009-12"
X Link @d_stock07734 2025-10-14T14:42Z XXX followers, XXX engagements

"What would happen to the sp if Merck could front $NWBO over at least $10b for collaborations on combining its over XX new growth drivers with DCVax What would happen to the sp if Baker Brothers could make a big investment in $NWBO Amgen acquired Horizon $28b in cash and its Actimmune cannot bring big revenue unless it can be combined with the Direct. All the combinations Dr. Bosch showed in the presentation had 'I' which most likely stands for Interferon Gamma-1b (ACTIMMUNE)"
X Link @d_stock07734 2025-10-11T15:59Z XXX followers, 3612 engagements

"@mazzulo_lorie @andrewcaravello Did you see how Merck set up and acquired Immune Design I was wondering if Merck was trying to do the same on $NWBO. But Merck didn't make it"
X Link @d_stock07734 2025-10-16T05:11Z XXX followers, XXX engagements

"A collaboration trial between Merck and TILT Biotherapeutics on ovarian cancer. One of the conclusions is that Median progression-free survival and overall survival were XX and XXX days respectively. Oncolytic Adenovirus Coding for TNFa and IL2 (TILT-123) With Pembrolizumab or Pembrolizumab (Phase 1a and 2) and Pegylated Liposomal Doxorubicin (Phase 1b) as Treatment for Ovarian Cancer. (PROTA) The oncolytic adenovirus TILT-123 with pembrolizumab in platinum resistant or refractory ovarian cancer: the phase 1a PROTA trial"
X Link @d_stock07734 2025-10-13T05:17Z XXX followers, XXX engagements

"$NWBO Going through the products from some BPs and wondering if those products can be combined with DCVax to treat cancer is really a wonderful experience. ACTIMMUNE (interferon gamma-1b): No need to explain this one. Aimovig (erenumab-aooe) is a CGRP inhiibtor: The inhibition of CGRP may lead to an increase in the DC's antigen-presenting capacity potentially boosting T-cell activation. By blocking CGRP's suppressive effects CGRP inhibitors can allow for greater DC activation and higher production of pro-inflammatory cytokines like TNF- which CGRP normally represses. Blocking CGRP's influence"
X Link @d_stock07734 2025-10-16T15:29Z XXX followers, 2881 engagements

"$NWBO Dr. James Economou is a co-founder of Kite Pharma acquired later by Gilead in the amount of $11.9b. Dr. Economou did research on DC vaccine. Not sure if it is the same as DCVax-L. But one thing should be certain that Gilead should know about DCVax very well. Gilead is currently collaborating with Evoq on using DC vaccine to treat autoimmune diseases. Vaccine Therapy in Treating Patients With Liver Cancer Last Update Posted 2020-08-03 Study Start: 2001-01 Primary Completion (Actual): 2004-12 Study Completion (Actual): 2008-10 Enrollment (Actual): XX Study Type: Interventional Phase:"
X Link @d_stock07734 2025-10-07T18:04Z XXX followers, 1503 engagements